TABLE 1.
Amplicor HPV and HC-2 detection of HR HPV DNA in cervical specimens collected from women referred to colposcopy because of an ASC-US cytologya
| Diagnosis group | Total no. of specimens | No. of specimens with indicated results [(%, 95% CI); P value] in indicated assay |
|||
|---|---|---|---|---|---|
| HC-2 | Amplicor with cutoff at: |
||||
| 0.2 | 1.0 | 1.5 | |||
| All women | 396 | 129 (32.6, 28.1-37.3) | 164 (41.4, 36.7-46.3); 0.01 | 157 (39.7, 35.0-44.5); 0.05 | 156 (39.4, 34.7-44.3); 0.05 |
| No CIN | 316 | 81 (25.6, 21.1-30.7) | 113 (35.8, 30.7-41.2); 0.01 | 107 (33.9, 28.9-39.3); 0.03 | 106 (33.5, 28.6-38.9); 0.04 |
| CIN 1 | 47 | 20 (42.6, 29.5-56.7) | 23 (48.9, 35.3-62.8); 0.68 | 22 (46.8, 33.3-60.8); 0.84 | 22 (46.8, 33.3-60.8); 0.84 |
| CIN 2/3 | 29 | 27 (93.1, 72.0-99.2) | 26 (89.7, 72.8-97.2); 1.0 | 26 (89.7, 72.8-97.2); 1.0 | 26 (89.7, 72.8-97.2); 1.0 |
| CIN ? | 4 | 1 (0.3, 0.0-1.6) | 2 (0.5, 0.0-3.8); 1.0 | 2 (0.5, 0.0-3.8); 1.0 | 2 (0.5, 0.0-3.8); 1.0 |
a
Diagnoses were obtained at colposcopy with biopsy in the presence of cervical lesions. HPV DNA detection rates obtained with Amplicor using different cutoffs were compared with rates obtained with HC-2. HC-2, Hybrid Capture 2 assay; CIN, cervical intraepithelial neoplasia; CIN ?, CIN that could not be graded; CI, confidence interval.